A retrospective cohort study conducted by Palanca et al. at two European centers evaluated the effect of SGLT2 inhibitors on the kidney functions of subjects with T1D (empagliflozin for 113 subjects, dapagliflozin for 66, and canagliflozin for 20) over a 12-month period, and the overall changes in the eGFR and UACR from baseline to 12 months were not significant. Here, SLC5A2 is linked to type 1 diabetes mellitus.